Journal article
Letter: ACE2, IBD and COVID-19—why IBD patients may be at reduced risk of COVID-19
RE Prentice, D Tjandra, M Garg, JS Lubel, S Fourlanos, D Johnson, A Al-Ani, B Christensen
Alimentary Pharmacology and Therapeutics | WILEY | Published : 2020
DOI: 10.1111/apt.16063
Abstract
LINKED CONTENT This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804
Grants
Funding Acknowledgements
Declaration of personal interests: Doug Johnson has served as speaker for Pfizer. Mayur Garg has served on the advisory board of Pfizer and Pharmacosmos and has received speaker fees, research or travel grants from Abbvie, Janssen, Pfizer, Pharmacosmos, Shire, Takeda and Vifor. Britt Christensen has received speaking fees from Abbvie, Jannsen, Pfizer, Takeda and Ferring, research grants from Janssen and Ferring Pharmaceuticals and served on the advisory board of Gilead and Novartis.